Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VCP | P55072 | 6/20 | 0.50 |
| ▸ | KDR | P35968 | 6/20 | 0.48 |
| ▸ | FLT1 | P17948 | 5/20 | 0.48 |
| ▸ | FLT4 | P35916 | 5/20 | 0.48 |
| ▸ | SIRT7 | Q9NRC8 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | IMPDH2 | P12268 | 2/20 | 0.42 |
| ▸ | SYK | P43405 | 1/20 | 0.41 |
| ▸ | EGFR | P00533 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | GLA | P06280 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4188112 | 0.81 | KDR (0.56) | VCPKDRFLT1FLT4SIRT7 | |
| SCHEMBL21311878 | 0.80 | VCP (0.64) | VCPKDRFLT1FLT4SIRT7 | |
| SCHEMBL21311902 | 0.79 | VCP (0.68) | VCPKDRFLT1FLT4SIRT7 | |
| SCHEMBL4174334 | 0.77 | TUBB4A (0.62) | VCPKDRFLT1FLT4IMPDH2 | |
| SCHEMBL5184578 | 0.76 | KDR (0.72) | VCPKDRFLT1FLT4IMPDH2 | |
| SCHEMBL14134239 | 0.75 | KDR (0.66) | VCPKDRFLT1FLT4SIRT7 | |
| SCHEMBL14058111 | 0.73 | KDR (0.45) | VCPKDRFLT1FLT4SIRT7 | |
| SCHEMBL14057525 | 0.72 | TRPV1 (0.66) | VCPKDRFLT1FLT4SIRT7 | |
| SCHEMBL14058473 | 0.72 | KDR (0.67) | VCPKDRFLT1FLT4SIRT7 | |
| SCHEMBL13605799 | 0.72 | VCP (0.60) | VCPKDRFLT1FLT4IMPDH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090318438-A1 | Heterocyclic compounds and their use as anticancer agents | CHEN XIAOLING | 2009-12-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090318438-A1 | Heterocyclic compounds and their use as anticancer agents | TP53, MCL1, VHL | VCP 1689/4885KDR 3284/4885FLT1 3408/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.